Lars R. Perk

3.0k total citations
23 papers, 2.4k citations indexed

About

Lars R. Perk is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lars R. Perk has authored 23 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Radiology, Nuclear Medicine and Imaging, 8 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lars R. Perk's work include Radiopharmaceutical Chemistry and Applications (17 papers), Medical Imaging Techniques and Applications (8 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Lars R. Perk is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (17 papers), Medical Imaging Techniques and Applications (8 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Lars R. Perk collaborates with scholars based in Netherlands, United States and Canada. Lars R. Perk's co-authors include Gerard W.M. Visser, Guus A.M.S. van Dongen, Maria J.W.D. Vosjan, Elisabeth G.E. de Vries, Marjolijn N. Lub–de Hooge, Marianne Budde, Garry E. Kiefer, Paul Jurek, Marijke Stigter‐van Walsum and Guus A.M.S. van Dongen and has published in prestigious journals such as Journal of Clinical Oncology, Nature Protocols and Molecules.

In The Last Decade

Lars R. Perk

23 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lars R. Perk Netherlands	17	1.8k	826	600	481	154	23	2.4k
Maria J.W.D. Vosjan Netherlands	18	1.6k 0.9×	701 0.8×	458 0.8×	588 1.2×	79 0.5×	23	2.1k
Guus A.M.S. van Dongen Netherlands	25	1.1k 0.6×	784 0.9×	416 0.7×	617 1.3×	202 1.3×	56	2.2k
Kayhan Garmestani United States	36	2.4k 1.4×	815 1.0×	754 1.3×	424 0.9×	81 0.5×	68	3.1k
Marco Chinol Italy	32	1.7k 1.0×	1.5k 1.8×	383 0.6×	354 0.7×	164 1.1×	95	3.5k
Elisabeth von Guggenberg Austria	29	1.5k 0.8×	1.5k 1.8×	747 1.2×	388 0.8×	174 1.1×	76	3.0k
Melpomeni Fani Switzerland	34	2.1k 1.2×	2.1k 2.5×	532 0.9×	543 1.1×	174 1.1×	92	3.8k
C. Willemien Menke‐van der Houven van Oordt Netherlands	25	1.1k 0.6×	1.0k 1.3×	428 0.7×	377 0.8×	327 2.1×	99	2.1k
Irina Velikyan Sweden	25	1.5k 0.9×	990 1.2×	423 0.7×	394 0.8×	82 0.5×	78	2.5k
Thijs H. Oude Munnink Netherlands	17	944 0.5×	896 1.1×	436 0.7×	467 1.0×	237 1.5×	43	1.8k
Alain Faivre-Chauvet France	28	1.7k 1.0×	720 0.9×	429 0.7×	421 0.9×	79 0.5×	106	2.4k

Countries citing papers authored by Lars R. Perk

Since Specialization

Citations

This map shows the geographic impact of Lars R. Perk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars R. Perk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars R. Perk more than expected).

Fields of papers citing papers by Lars R. Perk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars R. Perk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars R. Perk. The network helps show where Lars R. Perk may publish in the future.

Co-authorship network of co-authors of Lars R. Perk

This figure shows the co-authorship network connecting the top 25 collaborators of Lars R. Perk. A scholar is included among the top collaborators of Lars R. Perk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars R. Perk. Lars R. Perk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Derks, Yvonne H. W., Melline G.M. Schilham, Alexander Hoepping, et al.. (2022). An Explorative Study of the Incidental High Renal Excretion of [18F]PSMA-1007 for Prostate Cancer PET/CT Imaging. Cancers. 14(9). 2076–2076. 7 indexed citations

Perk, Lars R., et al.. (2021). Optimised GMP-compliant production of [18F]DPA-714 on the Trasis AllinOne module. EJNMMI Radiopharmacy and Chemistry. 6(1). 20–20. 8 indexed citations

Perk, Lars R., et al.. (2018). Production of novel diagnostic radionuclides in small medical cyclotrons. EJNMMI Radiopharmacy and Chemistry. 3(1). 3–3. 79 indexed citations

Janssen, Bieneke, Daniëlle J. Vugts, Uta Funke, et al.. (2014). Synthesis and initial preclinical evaluation of the P2X₇ receptor antagonist [¹¹C]A‐740003 as a novel tracer of neuroinflammation. Journal of Labelled Compounds and Radiopharmaceuticals. 57(8). 509–516. 71 indexed citations

Watering, Floor C. J. van de, Mark Rijpkema, Lars R. Perk, et al.. (2014). Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients. BioMed Research International. 2014. 1–13. 102 indexed citations

Hofman, Mark B.M., et al.. (2013). Technical Note: Building a combined cyclotron and MRI facility: Implications for interference. Medical Physics. 40(1). 12303–12303. 8 indexed citations

Funke, Uta, Daniëlle J. Vugts, Bieneke Janssen, et al.. (2013). ¹¹C‐labeled and ¹⁸F‐labeled PET ligands for subtype‐specific imaging of histamine receptors in the brain. Journal of Labelled Compounds and Radiopharmaceuticals. 56(3-4). 120–129. 17 indexed citations

Vosjan, Maria J.W.D., Lars R. Perk, Rob C. Roovers, et al.. (2011). Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET. European Journal of Nuclear Medicine and Molecular Imaging. 38(4). 753–763. 92 indexed citations

Vosjan, Maria J.W.D., Lars R. Perk, Gerard W.M. Visser, et al.. (2010). Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nature Protocols. 5(4). 739–743. 345 indexed citations

10.

Dijkers, Eli, Jos G. W. Kosterink, Lars R. Perk, et al.. (2009). Development and Characterization of Clinical-Grade ⁸⁹Zr-Trastuzumab for HER2/neu ImmunoPET Imaging. Journal of Nuclear Medicine. 50(6). 974–981. 271 indexed citations

11.

Perk, Lars R., Maria J.W.D. Vosjan, Gerard W.M. Visser, et al.. (2009). p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. European Journal of Nuclear Medicine and Molecular Imaging. 37(2). 250–259. 175 indexed citations

12.

Tijink, Bernard M., Lars R. Perk, Marianne Budde, et al.. (2009). 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy. European Journal of Nuclear Medicine and Molecular Imaging. 36(8). 1235–1244. 84 indexed citations

13.

Aerts, Hugo J.W.L., Ludwig J. Dubois, Lars R. Perk, et al.. (2008). Disparity Between In Vivo EGFR Expression and ⁸⁹Zr-Labeled Cetuximab Uptake Assessed with PET. Journal of Nuclear Medicine. 50(1). 123–131. 174 indexed citations

14.

Perk, Lars R., Marijke Stigter‐van Walsum, Gerard W.M. Visser, et al.. (2008). Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. European Journal of Nuclear Medicine and Molecular Imaging. 35(10). 1857–1867. 80 indexed citations

15.

Nagengast, Wouter B., Elisabeth G.E. de Vries, Geke A.P. Hospers, et al.. (2007). In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft. Journal of Nuclear Medicine. 48(8). 1313–1319. 246 indexed citations

16.

Hooge, Marjolijn N. Lub–de, Piet L. Jager, Adrienne H. Brouwers, et al.. (2007). Characterization of ⁸⁹Zr-trastuzumab for clinical HER2 immunoPET imaging. Journal of Clinical Oncology. 25(18_suppl). 3508–3508. 16 indexed citations

17.

Dongen, Guus A.M.S. van, Gerard W.M. Visser, Marjolijn N. Lub–de Hooge, Elisabeth G.E. de Vries, & Lars R. Perk. (2007). Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications. The Oncologist. 12(12). 1379–1389. 249 indexed citations

18.

Perk, Lars R., Otto Visser, Marijke Stigter‐van Walsum, et al.. (2006). Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging. 33(11). 1337–1345. 122 indexed citations

19.

Visser, Otto, et al.. (2006). Radioimmunotherapy for Indolent B-Cell Non-Hodgkin Lymphoma in Relapsed, Refractory and Transformed Disease. BioDrugs. 20(4). 201–207. 3 indexed citations

20.

Jong, Hugo W. A. M. de, Lars R. Perk, Gerard W.M. Visser, et al.. (2006). High Resolution PET Imaging Characteristics of /sup68/Ga, /sup124/I and /sup 89/Zr Compared to /sup 18/F. Pure Amsterdam UMC. 3. 1624–1627. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact